US20030068331A1 - Gum resin as a carrier for topical application of pharmacologically active agents - Google Patents

Gum resin as a carrier for topical application of pharmacologically active agents Download PDF

Info

Publication number
US20030068331A1
US20030068331A1 US10279704 US27970402A US2003068331A1 US 20030068331 A1 US20030068331 A1 US 20030068331A1 US 10279704 US10279704 US 10279704 US 27970402 A US27970402 A US 27970402A US 2003068331 A1 US2003068331 A1 US 2003068331A1
Authority
US
Grant status
Application
Patent type
Prior art keywords
skin
composition
agent
symptoms
pharmacologically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US10279704
Other versions
US8648082B2 (en )
Inventor
Alex Battaglia
Eva Beim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Advanced Resin Therapeutics Inc
Original Assignee
Alex Battaglia
Eva Beim
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465Nicotine; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53861,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/30Cosmetics or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toilet preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494Cosmetics or similar toilet preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/92Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015Drug-containing film-forming compositions, e.g. spray-on
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILET PREPARATIONS
    • A61Q17/00Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005Antimicrobial preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILET PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILET PREPARATIONS
    • A61Q3/00Manicure or pedicure preparations

Abstract

The invention provides a biological dressing for treatment of a dermatological disease comprised of a gum resin, a topically acceptable volatile solvent, and a pharmacologically active agent. The gum resin is present in a suitable amount that the composition, when the solvent evaporates, will dry to form a solid coating that sticks to the skin or mucosal membrane to which the composition is applied and maintain the pharmacologically active agent over a sustained period of time in contact with sites on the skin or mucosal membranes exhibiting symptoms of the disease. Methods are provided for treating symptoms of dermatological diseases with such a pharmacological composition. Biological dressings including tincture of benzoin and clotrimazole are shown to be efficacious for the long-term amelioration of symptoms of athlete's foot.

Description

    CROSS REFERENCE TO RELATED APPLICATIONS
  • This application is a continuation in part of U.S. Ser. No. 10/053,313 filed Jan. 18, 2002 which claims benefit of priority to provisional application U.S. Ser. No. 60/299,377 filed Jun. 18, 2001, which disclosures are hereby incorporated by reference.[0001]
  • INTRODUCTION
  • 1. Technical Field [0002]
  • The invention relates to gum resin or other film forming agent based biological dressings that adhere to the skin and contain one or more pharmacologically active agents for the treatment of symptoms relating to dermatological diseases and those affecting mucous membranes. The invention is exemplified by biological dressings comprising tincture of benzoin and clotrimazole for the treatment of athlete's foot. [0003]
  • 2. Background [0004]
  • For many forms of dermatological conditions, the powders, sprays, solutions, lotions and creams available over-the-counter lack effectiveness. The reason for this varies, from poor delivery of the medication to the source or cause of the condition; to loss of the medication through abrasion from normal activity of the patient, to absorption of medications applied to the skin by the patient's socks or clothes. For these various reasons, currently available commercial medications are prone to come off easily once applied to the affected area, and consequently much of the medication is wasted, either through over application in an attempt to anticipate the problem, or in medicine quickly being dispersed away from the site. The medications for these conditions typically require at least 2 to 4 weeks of continuous treatment, and thus often fail due to this poor delivery. [0005]
  • A further problem with the use of existent medications is the lack of compliance by patients. Due to the mess and difficulty of use, patients will often use these over the counter medications only until their symptoms abate and then they will stop the medication, before the recommended course of treatment is completed, and hence often before the infection has truly cleared. Though momentarily abated, the infection then begins to take hold again, and in a matter of days or weeks a full blown infection occurs again. In many cases the patient will repeat using the over the counter medication until the symptoms clear, and again stop the medication with the first sign of abatement, with the whole cycle repeating. [0006]
  • Hence, there is a need for a clean and inexpensive vehicle/carrier of topically applied medications that increases the convenience and effectiveness of the treatment and decreases the necessary time for the treatment. It is preferably associated with less waste and lower cost and ultimately leads to improved treatment of patient symptoms and increased patient satisfaction. [0007]
  • 3. Description of Related Art [0008]
  • In medicine, tincture of benzoin and mastic gum (Mastisol) have been employed to form a sticky coating on skin prior to the placement of adhesive preparations. Tincture of benzoin has also been used to form a biologic dressing over superficial cutaneous wounds as well as apthous ulcers (canker sores). However, the general use of gum resins, such as mastic gum and benzoin gum, as semi-permanently applied carriers for increasing the efficacy and usefulness of topological of pharmacological agents has not been disclosed. [0009]
  • A tincture of benzoin has been used with podophyllin resin (10-25%) in the treatment of genital warts. It is considered by many to be cumbersome and inconvenient (see U.S. Pat. Nos. 5,063,065 and 5,167,649). Unfortunately, podophyllin resin is toxic, and even when applied in a tincture of benzoin, this agent must be removed by rigorous washing 1 to 6 hours post-application. Due to the problems associated with using podophyllin resin in tincture of benzoin, other carriers have been sought. As an example, in the treatment of genital warts, Goh, et al. ([0010] Singapore Med J (1998) 39:17-19) reports that podophyllin prepared in 0.25% ethanol can be self-applied and is as efficacious as podophyllin prepared in tincture of benzoin and applied in the clinic. Use of tincture of benzoin as a biological bandage with compounds that it is desirable to have in long contact with the skin has not been reported.
  • SUMMARY OF THE INVENTION
  • Compositions and methods are provided for increasing the effectiveness of treatment of dermatological disorders on the skin or a mucous membrane of a mammal by using a gum resin or other film forming agent as a carrier for a pharmacologically active agent. The pharmacological compositions are comprised of a gum resin or other film forming agent, at least one topically acceptable pharmacologically active agent for treatment of a dermatological disorder other than the gum resin or other film forming agent, wherein the active agent is non-toxic to the mammal being treated when left in contact with the lesion of interest for at least 6 hours, and a topically acceptable volatile solvent. The compositions optionally can include a penetration enhancer. The methods of treating symptoms of a dermatological disorder include the steps of contacting affected sites on the skin of a patient in need thereof with the pharmacological composition comprised of a gum resin or other film forming agent, a pharmacological agent or agents, and an evaporative solvent, and allowing it to dry to form a biological dressing. The biological dressing comprises a sticky film of gum resin or other agent which forms a film on the skin and a pharmacologically active agent; the latter remains on the skin or mucous membrane after the volatile solvent has evaporated from the resin or other film-forming composition. The dressing forms a hydrophobic, protective film that provides sustained release of the pharmacologically active agent at the site of application. The invention finds use in the treatment of dermatological disorders such as infection, inflammation, and hyperproliferation of epidermal cells. [0011]
  • DETAILED DESCRIPTION OF THE INVENTION
  • Compositions and methods are provided for the convenient and effective treatment of at least one symptom of a dermatological disorders in a mammal, particularly a human, in need thereof, with a biological dressing. By “biological dressing” or “biologic dressing” or “biologic bandage” is intended a non-occlusive but adherent pharmacological composition that is formed by drying on the skin a pharmacologic composition comprised of a gum resin, such as benzoin or mastic gum or other composition that can form a barrier film on the skin, such as compositions that are used as skin wound sealing agents, a pharmacologically active agent and topically acceptable volatile solvent, such as ethanol. The biologic dressing forms a protective coating at the site(s) on the skin or mucosal membrane exhibiting symptoms of the disorder and also acts as a reservoir for the pharmacolocally active agent(s) to provide sustained delivery of an appropriate medication or combination of medications to the site. The skin disorder symptoms to be treated include skin and mucosal membrane lesions, inflammation, itching, scaling and pain. The disorders include viral, fungal and bacterial infections, inflammatory conditions, and hyperproliferative disorders. The pharmacological agent(s) can include topically active agents that can be used to ameliorate skin disorder symptoms, including antimicrobial and antiviral agents, anti-inflammatory agents, analgesics and anesthetics. As desired, the effectiveness of the pharmacological agent(s) optionally can be increased by including skin a penetration enhancer in the pharmacologic composition. The biological bandage is easily removed using a solvent such as ethanol. Since the coating that contains the medication stays in place until such deliberate removal, the effectiveness of the treatment is increased since the skin is exposed to the active ingredient for a longer period of time. This also allows for a decreased treatment time, and, ultimately, improved treatment of symptoms and increased patient satisfaction. Thus, compositions of the invention can be used to improve delivery of medications that are soluble in organic solvents such as alcohols that are typically applied topically for the treatment dermatologic disorders. [0012]
  • The advantages of the subject invention include a more specifically directed application of medications to sites affected by a skin disorder, and extended retention on the skin of the medication because the film is resistant to water and abrasion by clothing. Additionally, the vehicle is relatively inexpensive, is pleasant smelling, and the bandage can be conveniently and easily removed, for example with alcohol, when desired. Many dermatological conditions are exacerbated by moisture so the water repellent qualities of the dressing also protect the skin from further damage. The biological dressings are designed to be directly applied to a lesion needing treatment, and left in place for an extended period of time, without requiring conventional adhesive bandages. It is intended that the dressing need only be washed from the lesion for purposes of convenience and cleanliness. The biological dressings of the subject invention are cleaner and easier to apply than conventional dressings and existing medications, have less waste and are more economical, allowing for more efficient, efficacious and palatable relief of symptoms or recovery from the skin disorder being treated. Overall treatment success is increased by decreasing the time required for therapy, for example for athlete's foot, from about four weeks to seven to ten days while decreasing the total amount of medication needed and improving patient compliance. [0013]
  • Further advantages of the subject invention include that various of the gum resins that find use, including benzoin and mastisol, and wound sealing agents are already approved for human use and have been tested and found to be safe for topical application on non-human mammals; the wound sealing agents have the advantage of being able to deliver alcohol insoluble medications while reducing pain during application to an open wound. [0014]
  • The biological dressings are prepared by drying on the skin, a pharmacological composition comprising an agent that can be used to ameliorate the symptoms of a dermatological disease and a gum resin dissolved in a volatile solvent. Generally, the pharmacological composition is prepared as a sticky slurry or solution of the film forming agent and the pharmacologically active agent that can be applied to a site on the skin or a mucosal membrane. The consistency of the pharmacological composition can be varied by adjusting the ratio of solvent to gum resin in the composition to achieve the desired consistency for application to a particular site. For areas where evaporation of solvent may be slower, for example, application to lesions on a mucosal membrane such as the gums, it may be desirable to prepare the composition as a paste and to use a more volatile solvent, whereas for application to hard to reach areas, such as between the toes, it may be desirable to prepare a less viscous composition that can be applied thinly to the affected areas. However, for treatment of more severe lesions in non-visible areas, due to an athlete's foot infection for example, application of a more viscous preparation may be preferred. For those of the wound sealing agents that come in an un-polymerized or liquid form that, once in contact with skin or mucosa, develops into a dry adhesive layer or film, no solvent is generally necessary other than what may be necessary to properly blend in the pharmacologically active agent.. [0015]
  • The relative proportions of the gum resin or other film forming agent, the pharmacologically active agent or agents and the evaporative solvent in the preferred composition can vary widely, and depend upon the specific intended use of the biological dressing. Precise preferred ratios depend to some extent on the rate of release of the pharmacologically active agent from the film, the desired stickiness of the residual film, and the area of application. For example, if the intended application is to an affected area on the face, the preferred composition would have a lower proportion of gum resin or other film forming agent, to allow for a more thinly applied and less visible and less sticky medical dressing. Generally, the pharmacological compositions of the subject invention will have at least about 10% gum resin or other film forming agent, more likely about 20%, 30% or 40% gum resin or other film forming agent, and as much as 50% or 60% gum resin or other film forming agent. [0016]
  • The stickiness of the biological dressings is provided by the use of a gum resin or other film forming agent. The gum resins that are used generally are naturally occurring gum resins, such as those that are harvested from trees, although gum resins also may be prepared by synthetic means (see for example, U.S. Pat. Nos. 5,644,049, 5,429,590 and 4,307,717). Preferred gum resins include benzoin resinous exudate harvested from Styracaceae trees, including Benzoin Siam from Styrax Tonkinesis and Benzoin Sumatra from Styrax Benzoin. Tincture of benzoin and benzoin compound tincture is readily available through numerous commercial sources, including many drug stores and suppliers of surgical goods. Another resinous tree exudate that is preferred and is commonly used in the medical arts for enhancing the adherence of surgical bandages, is mastic gum, which is harvested from [0017] Pistacia lentiscus. A tincture of mastic gum (Mastisol) is produced by Ferndale Laboratories in Ferndale, Mich. and is also available through suppliers of surgical goods. Other gum resins that can be used include the gum resin exudate from Burserceae trees, including Boswellia serrata (also known as Boswellin), Boswellia dalzielli, Boswellia carteri (gum olibanum) and Canarium luzonicum or Canarium commune (Elemi gum or resin). Additional resinous exudates contemplated from other tree species include Eucalyptus species (Eucalyptus globulus) and Myrtaceae “Tea-tree” species (Melaleuca alternifolia, Leptospermum scoparium, and Kunzea ericoides). Many naturally occurring gum resins themselves have pharmacological properties, and their topical application may cause irritation in certain patients or exacerbate certain conditions. Prudent choice of the gum resin to be used in preparing a particular biological dressing takes into consideration the dermatological disorder to be treated and the sensitivities of a particular patient's skin.
  • In addition to the gum resins, biologic dressings can be made from several classes of adhesive polymers including acrylic polymers (e.g. cyanoacrylates), polyisobutylenes and silicones. Examples of the acrylic polymers include acrylate-vinylacrylate, dimethylaminoethylmethacrylate, methacrylic esters, N-2-butylcyanoacrylate, 2-octylcyanoacrylate, polyacrylic acid, polyaminomethylmethacrylate and polymethlmethacrylate. Polyisobutylenes (a sub-type of polyolefins) are pressure sensitive adhesives made by blending multiple molecular weights to achieve desired adhesive and drug-carrier properties. Silicones are available in the form of gels, liquids, or elastomers, depending on the nature of side groups and the interchain cross-linking. Other potential adhesive vehicles include hydrogel polymers such as poly (oxypropylene-co-oxyethene) glycol, cellulose bioadhesives such as hydroxypropylmethyl-cellulose, synthetic laticies such as polyvinyl acetate and ethylene vinyl-acetate, mucosal adhesives such as polyoxyethylene, pyroxylin solutions, and the iodophors. Commercial sources of film forming agents that can be combined directly with a pharmacologically active agent include Dermabond (Ethicon) which is a formulation of 2-octylcyanoacrylate; Liquid Band Aid (Johnson and Johnson) which is also a formulation of 2-octylcyanoacrylate; Liquidenm, Soothe-N-Seal, Nexa Band ( all from Closure Medical Co), all formulations of cyanoacrylate; “New-Skin” (New Skin) containing pyroxylin; and hydrogels containing poly (oxypropylene-co-oxyethene) glycol (MedLogic). [0018]
  • A desirable feature of the subject compositions is that they form an adherent and protective film or biological bandage over a dermatologic lesion. To effect this attribute, the pharmacological composition is prepared with a volatile solvent that evaporates to leave a hydrophobic coating comprised of the gum resin or other film forming agent and the pharmacological agent on the skin. Volatile solvents for use in the subject compositions include alcohols such as methanol, ethanol, propanol, and isopropanol, and ketones, such as acetone. Other evaporative compounds may also find use, so long as they are compatible with other components of the pharmacological composition and topically acceptable to the majority of patients. The gum resin of choice is diluted in the volatile solvent such that the concentration of solvent comprises at least about 40% or 50% (v/v or v/w), more commonly at least about 60%, 70% or 80%, or as much as about 90% of the total composition. A particularly preferred composition is a tincture of benzoin, which is comprised of benzoin in about 60%, 70%, 80% or 90% ethanol. [0019]
  • The pharmacological agent or agents included in the pharmacological compositions will depend upon the dermatological disorder being treated. To allow for extended contact of the biological dressing with the lesion under treatment, pharmacological agents chosen should be efficacious without being locally or systemically toxic or caustic to the mammal to which the medicated dressing is administered. A biological dressing of the subject invention is intended to remain at the site of application for at least 6 hours, more often as long as 8, 10 or 12 hours, sometimes as long as 16, 18 or 20 hours, and for certain treatments, as long as 24, 36 or 72 hours or even longer prior to removal. The time of treatment desired is based at least in part upon the nature of the condition to be treated and the pharmacological agent(s) that are being used. In general, the pharmacological compositions are formulated so that the concentration of the pharmacological agent(s) that is in the biological bandage approximates the concentration of agent that is used in existing topical formulations. However, because the adherent properties of a gum resin-based biological dressing allow for extended and continuous exposure of a skin lesion to drug, reduced concentration formulations are possible and even preferred. The amount to be used can therefore be adjusted as appropriate. Generally, the amount used will be within the range of ±25% of the indicated concentration, preferably within ±10% of the indicated concentrations. In the following paragraphs, the percentages appearing in parenthesis after the name of a particular agent represent the concentration(s) of agent that is(are) used in existing topical formulations. [0020]
  • The subject biological dressings find particular use in treating numerous dermatological disorders, including superficial infections (fungal, bacterial, viral and parasitic), and inflammatory skin disorders. Additional uses include sustained delivery of pharmacological agents for hair growth stimulation and hair growth retardation, skin pigmenting and pigmentation removal agents, sunscreens, insect repellents, anti-anginal, antiperspirant and anti-nausea agents. [0021]
  • Superficial fungal infections treatable by the subject compositions include those caused by mold-like fungi (dermatophytes or tinea) or yeast-like fungi (Candida) that are confined to the stratum corneum or squamous mucosa. Particularly considered is the treatment of tinea infections including athlete's foot (tinea pedis), ringworm (tinea capitis), jock itch (tinea cruris), tinea corporis, tinea manuum and tinea versicolor. Other dermatological fungal infections treatable with the described biological dressings include Candida, Epidermophyton, Microsporum, Trichophyton and Pityrosporum infections. Compositions for the treatment of superficial fungal infections will include at least one anti-fungal pharmaceutical agent. Anti-fungal agents for use in a biological dressing composition include those well-known in the art, such as clotrimazole (0.5%, 1.0%, 2.0%), ketoconazole ((1%, 2%), econazole (1%), miconazole (2%), terconazole (0.4%), butoconazole (2%), oxiconazole (1%), sulconazole (1%), ciclopirox olamine (1%), haloprogin (1%), tolnaftate (1%), amphotericin B (3%), butenafine (1.0%), terbinafine (1.0%), naftifine, nystatin and griseofulvin. References that can be consulted to aid in the selection of an appropriate pharmacological agent include Goodman and Gilman's “The Pharmacological Basis of Therapeutics”, 9[0022] th Edition, 1996, Pergamon Press, New York, and the lastest edition of the Physician's Desk Reference published by Medical Economics Company, Montvale, N.J.).
  • Secondary bacterial infections that may arise in conjunction with the primary fungal infection can be treated simultaneously or prophylactically by additionally including a topically compatible antibiotic pharmacological agent in the biological dressing. Antibiotic medications known in the art that will find use in preparation of the subject compositions include clindamycin (1%), erythromycin (1.5%, 2.0%), tetracycline (3%), mupirocin (2.0%), gentamycin (0.1%), metronidizole (0.75%, 1%), bacitracin, neomycin and polymyxin B. A composition with a combination of antibiotics against different strains of bacteria will be preferred for certain treatments. A steroidal pharmacological agent, such as betamethasone (0.025%, 0.05%, 0.1%), in a biological dressing intended to treat a fungal infection can additionally be included to enhance the retraction of the lesion. [0023]
  • Biological dressings having an antibiotic medication as the primary pharmacological agent can be prepared to treat other skin disorders for which such medications are traditionally used, including as impetigo contagiosa, acne vulgaris, other superficial skin infections of unknown etiology, and post-operative superficial skin infections (e.g., infections that occur around the insertion of a catheter). Wound healing can be aided and colonization of wounds (i.e. isolated areas with first-degree burns) can be inhibited by application of a biological dressing comprising silver sulfadiazine (1%). The particular antibiotic selected to include in the biologic dressing will of course depend on the agents to which the strain of bacteria causing the infection is sensitive, and the specific needs of the patient. [0024]
  • A gum resin or other film forming agent dressing can also be prepared for the treatment of superficial parasitic infections, such as scabies, nits and lice (including head lice and crab lice). For treating such infections, pharmacological compositions comprising miticides or pediculocides such as crotamiton (10%) or permethrin (5%), lindane (1%), malathion (0.003%, 0.06%, 0.5%), benzyl benzoate (26% to 30%), thiabendazole and pyrethrins. [0025]
  • For treating pain associated with arthritis, joint inflammation and muscle pain a gum resin or other film forming agent dressing can be prepared containing one or more active ingredients such as menthol (10%), methyl salicylate (10%) and capsaicin (0.01%-10%) or a corticosteriod (see below for appropriate compounds and dosages). The biological dressing compositions also find use in the treatment of dermatological inflammatory disorders, wherein the primary pharmacological agent included is a corticosteroid. Particularly contemplated is the treatment of corticosteroid-responsive inflammatory conditions, such as atopic dermatitis or eczema, seborrheic dermatitis, some forms of psoriasis, apthous ulcers (canker sores), superficial skin lesions due to contact with poisonous plants such as poison oak or poison ivy, insect bites, and other skin rashes of unknown etiology. Steroidal agents of all different grades (1-7) that are known in the art can be included in a biological dressing preparation, such as betamethasone (0.025%, 0.05%, 0.1%), clobetasol (0.05%), diflorasone (0.05%), amcinonide (0.1%), desoximetasone (0.05%, 0.25%), fluocinonide (0.05%), halsinonide (0.1%), triamcinolone (0.025%, 0.1%, 0.5%), hydrocortisone (0.1%, 0.2%, 0.5%, 1.0%, 2.5%), flurandrenolide (0.05%), alclometasone (0.05%), fluocinolone (0.01%, 0.025%, 0.2%), desonide (0.05%), desamethasone (0.1%) and methylprednisolone (1.0%), clocortolone (0.1%), fluticasone (0.05%, 0.005%), mometasone (0.1%), prednicarbate (0.1%), amcinonide (0.1%), and halobetasole (0.05%). The particular corticosteriodal agent selected will depend on the patient and the dermatological disorder being treated. [0026]
  • For the treatment of certain skin disorders, non-steroidal drugs may be appropriate. As an example, a biological dressing comprising salicylic acid (2.5%, 5%, 10%, 20%, 40%, 60%) would be suitable for the treatment of acne, psoriasis, warts, and other hyperkeratotoic disorders. Cantharidin (0.7%), imiquimod (5%), and podofilox (0.5%) are other examples of pharmacological agents for use in a biological dressing prepared for the treatment of warts, including genital warts. Other pharmacological agents suitable for the treatment of acne include tretinoin (0.025%, 0.05%, 0.1%, 0.2%), isotretinoin, adapaline (0.1%), azelaic acid (20%), clindamycin, erythromycin, tetracycline, benzoyl peroxide (2.5%, 5%, 10%), and sulfacetamide (10%). A gum resin or other film forming agent composition comprising metronidazole (0.75%) finds use in the treatment of rosacea. Biological dressings comprising anthralin (0.1%, 0.2%, 0.25%, 0.4% and 0.5%), calcipotriene (0.005%) and/or tazarotene find use in the treatment of psoriasis. [0027]
  • For certain inflammatory dermatological conditions, it may be desirable to include one or more anti-histamine compounds with a steroidal compound in the biological dressing compositions to aid in relieving itching that is often associated with inflammatory lesions. Histamine H[0028] 1 and H2 receptor blockers known in the art are of use in the preparation of biologic dressings for treating certain inflammatory skin conditions include the H1 blockers astemizole and terfenadine and the H2 blocker cimetidine.
  • Dermatological conditions which can be treated with phamacological composition in which an anti-histamine is the primary agent include urticaria, and itching associated with lymphoproliferative diseases such as polycythemia rubra vera and Hodgkin's disease. Oftentimes best results are achieved when using both an H[0029] 1 and an H2 blocker. Additionally, a medicated gum resin or other film forming agent dressing comprising the anti-pruritic doxepin (5%) finds use in relieving the itching in patients with certain types of eczema. Topical doxepin appears to work by preventing the effects of histamine.
  • A gum resin or other film forming agent carrier also finds use in the treatment of superficial dematological viral infections, whenever topical anti-viral medications would be indicated. Particularly considered is the administration of acyclovir (5%) for the treatment of viral infections caused by herpes (type 1 and type 2) simplex viruses, but a biological dressing can also be applied to superficial skin infections caused by papillomavirus (for example, common and genital warts). Other examples of anti-viral agents for use in a biological dressing include gancyclovir, penciclovir (1%), vidarabine (3%), idoxuridine (0.5%) and trifluridine. [0030]
  • A biological dressing also finds use in providing relief from pain associated with the lesions caused by some dermatological disorders. Particularly considered is treatment of the dermal pain that can be associated with varicella-zoster virus (shingles, chicken pox) with a topically compatible local anesthetic. A preferred pharmacological agent for use in a gum resin-based dressing prepared for treating pain associated with dermatological disorders is lidocaine (0.5%, 1%, 2%, 5%, 10%, 20%, 25%, see U.S. Pat. Nos. 5,709,869, 5,601,838, 5,589,180 and 5,411,738). Other local anesthetics chemically and/or pharmacologically related to lidocaine, or lidocaine hydrochloride, include bupivacaine hydrochloride (0.25%, 0.5%, 0.75%, 1.5%), etidocaine hydrochloride (1.0%, 1.5%, 3.0%), mepivacaine hydrochloride (1.0%, 1.5%, 2.0%, 3.0%, 5.0%), prilocaine hydrochloride (4.0%, 8.0%), and tetracaine hydrochloride (0.5%, 1.0%, 2.0%). Other preferred local anesthetics are those with low solubility in water, and which are particularly suited for sustained local anesthetic action when topically applied. Examples of local anesthetics with low solubility in water include benzocaine and the hydroiodide salt of tetracaine. Additional local anesthetics used in treating mucous membranes and the skin include dibucaine, dyclonine hydrochloride (0.5%, 1.0%), and pramoxine hydrochloride (1.0%), Another example of a pharmacological agent used topically to relieve dermatological pain includes capsaicin (0.025%). [0031]
  • Gum resin or other film forming agent compositions containing synthetic hormones find use in the treatment of indications associated with abnormal hormone production as well as contraception. For example, a gum resin or other film forming agent composition containing transdermal testosterone, generally about 2.5-5.0 mg per application, or equivalent other androgenic compound(s) in an appropriate amount can be used to treat young males with congenital or acquired primary hypogonadism, or congenital or acquired hypogonadotropic hypogonadism and other similar disorders. In women, a gum resin or other film forming agent composition containing estradiol (an active form of estrogen) or other equivalent estrogenic compound(s) in an appriopriate amount, can be used to treat the indications and symptoms associated with atrophic vaginitis, atrophic dystrophy of the vulva, menopausal symptoms, female hypogonadism, ovariectomy, primary ovarian failure, non-steroid dependent inoperable breast cancer and vasomotor symptoms associated with menopause and prevention of post-menopasual osteoporosis. A gum resin or other film forming agent composition containing an estrogenic compound, such as for example estradiol in an amount sufficient for the treatment of such indications is used. [0032]
  • A composition containing norethindrone (progestin) can be used to prevent pregnancy by inhibiting ovulation and thickening the mucosa of the cervix. In addition, a gum resin or other film forming agent composition containing a progestin compound such as norethindrone (0.14-0.25 mg per application) can be used for treating abnormal menstrual disorders such as amenorrhea, abnormal uterine bleeding and endometriosis, applications generally will be to the skin. The site of application of the gum resin or other film forming agent composition will vary depending upon the intended use. Generally the site of application will be to the skin at a location that will provide for absorption into the blood stream. Particularly in the case of treatments relating to the female genitalia, application can be intravaginally. [0033]
  • Gum resin or other film forming agent compositions are also suitable for sustained delivery of pharmacological agents use for hair growth retardation and stimulation. For treatments intending to stimulate hair growth, compositions comprising minoxidil (1%, 2%, 5%) are prepared. For other topical formulations that can be used with the gum resin or other film forming agents, see U.S. Pat. No. 6,184,249. For treatment intending to retard hair growth compositions comprising eflornithine hydrochloride (13.9%) are prepared. [0034]
  • A gum resin or other film forming agent vehicle additionally finds use in preparing protective compositions comprising sun protecting, ultraviolet absorptive agents. Sunscreens for use in a gum resin or other film forming agent-based dressing include aminobenzoate agents, such as p-aminobenzoic acid (PABA), ethyl 4-[bis(hydroxypropyl)] aminobenzoate, octyl dimethyl PABA, PABA propoxylate, glyceral PABA, 2-ethylhexyl PABA and pentyl PABA; cinnamate agents, such as cinoxate, diethanolamine-p-methoxy cinnamate, 2-ethylhexyl-p-methoxycinnamate and octyl methoxycinnamate; benzones, such as oxybenzone, dioxybenzone, sulisobenzone; salicylates, such as 2-ethylhexyl salicylate, triethanol amine salicylate, and octyl salicylate; and other sunscreen agents, such as titanium dioxide and zinc oxide. For use as a sunscreen, generally a thin gum resin or other film forming agent/ultraviolet absorptive agent preparation is applied to areas of the skin that will be exposed to the sun. For some situations, protection of exposed skin from the sun will be best accomplished by applying a thicker gum resin or other film forming agent formulation, for example, for application of sunscreen to protect the skin of the nose at high altitudes. Advantageously, a gum resin or other film forming agent/sunscreen compound formulation is particularly effective at providing long-lasting sun protection to exposed skin through resisting removal by abrasion or moisture [0035]
  • Gum resin or other film forming agent compositions may be prepared with pharmacological agents used for pigmenting or de-pigmenting the skin, for instance, for use in treating patients with vitiligo. For treatments intending to de-pigment or lighten isolated dermal areas, a pharmacologic composition comprising hydroquinone (2%, 3%, 4%) is prepared. For treatments intending to pigment desired areas of skin, a composition comprising a psoralen agent, such as methoxalen (1.0%), for combined use with UV light, is prepared. [0036]
  • A medicated dressing will also find use in the sustained delivery of anti-perspirants, anti-anginal, anti-nausea agents and anti-cancer agents. Particularly contemplated are compositions comprising aluminum chloride (20%), for the inhibition of perspiration of isolated dermal areas, for instance to aid in carrying out surgical procedures. A gum resin or other film forming agent composition comprising nitroglycerin (0.5%, 1.0%, 2.0%) will find use in the sustained transdermal delivery of this anti-anginal agent which can provide relief from chest pains. Relief from nausea, due to motion sickness for example, can be provided using a biological dressing comprising scopolamine. For anti-nausea purposes, a gum resin or other film forming agent/scopolamine composition would be applied, behind the ear for example, before the onset of activity that potentially would induce nausea. Additionally, a gum resin or other film forming agent dressing can be prepared for the sustained delivery of pharmacological agents useful in the treatment of superficial cancerous and pre-cancerous lesions. Particularly contemplated is the treatment of isolated actinic keratosis lesions with a biological dressing comprising 5-fluorouracil (5-FU; 5%, 10%). [0037]
  • A gum resin or other film forming agent carrier may also be prepared with an insect repellant as the pharmacologic agent. Examples of insect repellant compounds suitable for inclusion in a biological dressing include terpenoids, such as citronellal, geraniol, terpentine, pennyroyal, cedarwood, eucalyptus and wintergreen; benzoquinones; aromatics, such as cresols, benzaldehyde, cinnamic aldehyde, benzoic acids; and synthetic insect repelling agents, such as N,N-diethyl-m-toluamide (DEET), ethyl hexanediol, dimethyl phthalate, dimethyl ethyl hexanediol, carbate, butopyronoxyl, di-n-propyl isocinchonmeronate, N-octyl bicycloheptene, dicarboximide, and 2,3,4,5-bis(2-butylene)tetra-hydro-2-furaldehyde. For use as an insect repellent, a gum resin or other film forming agent preparation is preferably applied as a thin coat to areas of the skin most likely to be attacked by an insect. Preferably, the insect repellant compound used repels insects without irritating the skin. Advantageously, as with the sunscreen preparations described above, a gum resin or other film forming agent/insect repellent formulation is particularly effective at providing long-lasting insect repellency on the skin through resisting removal by abrasion or moisture. [0038]
  • Gum resin or other film forming agent compositions also find use in the treatment of drug addiction. Compositions containing nicotine, generally about in an amount sufficient to decrease nicotine addition, 14-22 mg per application, or other amounts as appropriate, find use in the reduction and/or cessation of cigarette smoking, chewing tobacco or other nicotine containing compounds. The compositions are applied to the skin in a location that provides sufficient absorption of the nicotine, typically the upper arm. As the need for nicotine decreases the dosage of nicotine in the composition can be adjusted downward. [0039]
  • Optionally, the biologic dressing may include a penetration enhancer, i.e., a chemical compound that, when included in a formulation, temporarily increases the permeability of the skin to a drug allowing more of the drug to be absorbed in a shorter period of time. Examples of penetration enhancers that can be used include dimethylsulfoxide, n-decyl methyl sulfoxide, N,N-dimethylacetamide, N,N-methyl-2-pyrrolidone and octylphenylpolyethylene glycols. [0040]
  • The biologic dressing may also include other pharmaceutically acceptable carriers as needed that do not adversely affect the effectiveness of the drug, or the resinous delivery vehicle and do not damage the skin to which it is applied. Suitable pharmaceutical carriers include sterile water; saline, dextrose; dextrose in water or saline; condensation products of castor oil and ethylene oxide combining about 30 to about 35 moles of ethylene oxide per mole of castor oil; liquid acid; lower alkanols; oils such as corn oil; peanut oil, sesame oil and the like, with emulsifiers such as mono- or di-glyceride of a fatty acid, or a phosphatide, e.g., lecithin, and the like; glycols; polyalkylene glycols; aqueous media in the presence of a suspending agent, for example, sodium carboxymethyl-cellulose; sodium alginate; poly(vinyl pyrrolidone); and the like, alone, or with suitable dispensing agents such as lecithin; polyoxyethylene stearate; and the like. The carrier may also contain adjuvants such as preserving stabilizing, wetting, emulsifying agents and the like. [0041]
  • The compounds of this invention can be administered in conjunction with a transdermal patch that can include the pharmacologic agent in a suitable solvent system with the film forming agent and a polyester patch. The compounds of the present invention also can be delivered through mucosal membranes. Transmucosal (i.e., sublingual, buccal, and vaginal) drug delivery provides for an efficient entry of active substances to the systemic circulation and reduces immediate metabolism by the liver and intestinal wall flora. Transmucosal drug dosage forms are held in contact with the mucosal membrane where they disintegrate and/or dissolve rapidly to allow immediate systemic absorption. For delivery to the buccal or sublingual membranes, an oral formulation is used which may as needed contain taste masking agents. The method of manufacture of these formulations is known in the art. [0042]
  • For aerosol administration, the pharmaceutical compositions are preferably supplied in finely divided form together with a surfactant and propellant as pharmaceutically acceptable carriers. The surfactant is nontoxic, and preferably soluble in the propellant. Representative of such agents are the esters or partial esters of fatty acids containing from 6 to 22 carbon atoms, such as caproic, octanoic, lauric, palmitic, stearic, linoleic, linolenic, olesteric and oleic acids with an aliphatic polyhydric alcohol or its cyclic anhydride. Mixed esters, such as mixed or natural glycerides, can be employed. [0043]
  • In practicing a method of treating the symptoms of a dermatological disease in a patient, the pharmacological composition in its original prepared form, is applied directly and specifically on the lesions or other damaged areas of skin requiring treatment. The biological dressing composition may initially be prepared in any form suitable for topical application, such as a paste, a liquid, a semi-solid, a gel, a suspension, an emulsion or the like, provided that the formulation allows the gum resin or other film forming agent carrier and pharmacologically active agent to effectively adhere together to the skin surface to which they are applied and to form a protective barrier over the skin once the volatile solvent has evaporated. To minimize waste, application is generally carried out by painting or swabbing the composition at the affected site or sites, but certain preparations can also be applied by spraying on the formulation, and allowing it to dry. [0044]
  • The biologic dressing composition can be applied wherever the patient has superficial skin lesions or infections, such as on cutaneous areas, mucous membranes, and mucocutaneous junctions (i.e., perianal, intertriginous and vulvovaginal areas). After application, the volatile solvent evaporates to leave a protective solidified, adherent and hydrophobic film or coating on the skin surface to which it has been applied. The solidified film residue comprises the gum resin or other film forming agent carrier, and the pharmacologically active agent or agents. By forming a barrier holding the pharmacologically active agent to the surface, the gum resin or other film forming agent permits a sustained, continuous release and a prolonged exposure to the agent or agents. Continuous exposure of the skin to the medication is maintained as long as the coating stays in place. The biologic dressing, therefore can effect symptomatic relief with less frequent applications. For most dermatological disorders treated using a gum resin or other film forming agent-based dressing, one or two daily applications will be sufficient to promote regression or disappearance of the targeted skin lesions. For certain less respondent lesions, three daily applications may be required to effect disappearance of symptoms. Other dermatological disorders may require application every second day to realize symptomatic relief. The composition conveniently can be removed at will, by application of an appropriate solvent, normally ethanol. The composition can also be removed by scrubbing with soap and water. [0045]
  • The subject compositions can be provided for use in one or more applications. For treatment with a pharmaceutical composition comprising an agent identified as one which is effective in treating the symptoms of a disease amendable to treatment by dermal application of medication, the subject compositions can be provided as kits for use in one or more doses. The kits include containers which can also constitute a delivery system, holding a composition comprising an effective agent either as concentrates (including lyophilized compositions), which may be further diluted prior to use or they may be provided at the concentration of use, where the containers may include one or more dosages. Conveniently, in the kits single dosages can be provided in sterile containers so that the physician or the patient may employ the containers directly, where the containers have the desired amount and concentration of agents. When the containers contain the formulation for direct use, usually there will be no need for other reagents for use with the method. The kits also can be in the form of a transdermal or transmucosal system for single or multiple applications. The containers can be made of plastic, glass, metal or such material deemed appropriate for each particular medication and can be light opaque as required for light sensitive formulations. The containers can be color-coded, each color being unique to a particular product and its respective active ingredient. The containers can also be color coordinated with the outer packaging to simplify marketing and consumer purchasing. Examples of containers that are also delivery systems are those that facilitate application of the subject compositions to the skin or mucosa. The delivery systems can be any of a wide assortment of types of applicators (e.g. bottles), shapes and sizes of containers such as roll-on, spray with either a manual or aerosolized delivery system, applicators with small padded applicator tips for the delivery of buccal mucosal medications or syringe type applicators for semisolid medication such as are described in U.S. Pat. No. 5,531,703 and references cited therein, particularly for the delivery of vaginal mucosal medications. [0046]
  • The subject compositions can be contained in packaging material, which comprises a label indicating that the subject compositions can be used to treat dermatologic disorders in humans or to treat other disorders in humans using transdermal delivery means. [0047]
  • The invention now being generally described, it will be more readily understood by reference to the following examples which are included for purposes of illustration only and are not intended to limit the present invention.[0048]
  • EXAMPLES Example 1
  • Treatment of Athlete's Foot (Tinea Pedis) with a Gum Resin-Based Biological Dressing Comprised of Tinture of Benzoin and Clotrimazole [0049]
  • Tincture of benzoin compositions are produced with standard tincture of benzoin (3M, Minneapolis, Minn.). Replicated experiments were performed with a composition comprising tincture of benzoin with 60% alcohol plus 1% clotrimazole. To determine efficacy in treating athlete's foot, the benzoin/clotrimazole composition was applied to cases of athlete's foot, replicated 5 times. In each replicate, the composition led to complete clearance of the athlete's foot within 1 week, when applied twice daily for 7 days. No allergic reaction was noted in this test, although the alcohol component reportedly led to stinging when applied to deep fissures. Minimal lint from the socks was noted on the coating where the composition was applied but was easily removed with ethanol. Efficacy of the benzoin/clotrimazole composition was compared to controls of tincture of benzoin alone and no treatment. The benzoin/clotrimazole composition provided symptomatic relief and led to healing more quickly than tincture of benzoin alone, though tincture of benzoin alone improved symptoms and signs more quickly when compared to no treatment. This is likely due to the fact that the sticky coating from the tincture tends to repel moisture. Efficacy of the benzoin/clotrimazole composition also was compared to commercially available medications such as Lamisil®, Lotrimin®, Mycelex® and Tinactin®. In comparison, the benzoin/clotrimazole composition greatly decreased the time necessary for treatment compared to formulations of each of the commercial medications, particularly when the commercial medications were administered in the form of powder, liquid, solution, spray or gel. The benzoin/clotrimazole composition also decreased the time necessary for treatment when compared to cream versions of the above medications and was much less messy than any of the commercial preparations tested. [0050]
  • The above results demonstrate the improved symptomatic relief from a dermatological disorder that can be achieved by administering a topically acceptable pharmacological agent in a gum resin carrier that forms a biological bandage in comparison presently available carriers. With a gum-resin-based biological dressing, relief from the unpleasant symptoms associated with a dermatological lesion is realized more efficiently and in a more convenient and palatable manner. [0051]
  • All publications and patent applications mentioned in this specification are indicative of the level of skill of those skilled in the art to which this invention pertains. All publications and patent applications are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporate by reference. [0052]
  • The invention now having been fully described, it will be apparent to one of ordinary skill in the art that many changes and modifications can be made thereto without departing from the spirit or scope of the appended claims. [0053]

Claims (32)

    What is claimed is:
  1. 1. A pharmacological composition comprising:
    a) a gum resin;
    b) at least one topically acceptable pharmacologically active agent other than said gum resin that is effective as a treatment for ameliorating symptoms of a disease of skin or a mucous membrane of a mammal, wherein said pharmacologically active agent can remain in contact with said skin or said mucous membrane greater than 6 hours without toxic effects to said mammal; and
    c) a topically acceptable volatile solvent for said gum resin and said pharmacologically active agent.
  2. 2. The composition according to claim 1, wherein said gum resin comprises benzoin.
  3. 3. The composition according to claim 1, wherein said topically acceptable volatile solvent comprises ethanol.
  4. 4. The composition according to claim 3, wherein said topically acceptable volatile solvent is ethanol and comprises about 60% to 90% of said composition.
  5. 5. The composition according to claim 1 wherein said pharmacologically active agent is an antimicrobial agent.
  6. 6. The composition according to claim 5 wherein said antimicrobial agent is an anti-fungal agent.
  7. 7. The composition according to claim 6, wherein said anti-fungal agent is clotrimazole.
  8. 8. The composition according to claim 7, wherein said clotrimazole is present as 1% of said composition.
  9. 9. The composition according to claim 1 wherein said pharmacologically active agent is a steroidal agent.
  10. 10. The composition according to claim 9, wherein said steroidal agent is betamethasone.
  11. 11. The composition according to claim 10, wherein said betamethasone is present as 0.025-0.05% of the composition.
  12. 12. The composition according to claim 1, wherein said pharmacologically active agent comprises both an antimicrobial agent and a steroidal agent.
  13. 13. The composition according to claim 1, further comprising a penetration enhancer.
  14. 14. A pharmacological composition comprising:
    a) a benzoin;
    b) clotrimazole; and
    c) ethanol.
  15. 15. A method of increasing the effectiveness of a treatment for ameliorating the symptoms of a dermatological disease in a patient in need thereof, said method comprising:
    a) contacting sites on the skin of said patient exhibiting symptoms of said dermatological disease with a pharmacological composition according to claim 1;
    and
    b) allowing said composition to dry so that it forms a film on said skin, so that the effectiveness of said treatment for ameliorating said symptoms is increased.
  16. 16. The method according to claim 15, wherein said dermatological disease is a fungal infection and said pharmacologically active agent is an anti-fungal compound.
  17. 17. The method according to claim 16, wherein said fungal infection is athletes foot.
  18. 18. The method according to claim 16 or 17, wherein said anti-fungal compound is clotrimazole at a concentration of about 1% by weight.
  19. 19. The method according to claim 15, wherein said dermatological disease is an inflammatory disease of the skin.
  20. 20. The method according to claim 19, wherein said inflammatory disease is selected from the group consisting of eczema, seborrheic dermatitis and psoriasis.
  21. 21. The method according to claim 19 or 20, wherein said pharmacologically active agent is an anti-inflammatory steroidal agent.
  22. 22. The method according to claim 21, wherein said anti-inflammatory steroidal agent is betamethasone at a concentration of about 0.025% to 0.05% by weight.
  23. 23. The method according to claim 15, wherein said dermatological disease is a bacterial infection.
  24. 24. The method according to claim 23, wherein said pharmacologically active agent is an anti-bacterial agent.
  25. 25. A method of producing a biological dressing as a treatment for ameliorating symptoms of a disease of skin or a mucous membrane, said method comprising:
    drying a composition according to claim on the skin or a mucosal membrane of a mammal at a site exhibiting symptoms of said disease so that it forms a film on said skin or mucosal membrane, whereby a biological dressing is obtained for ameliorating said symptoms.
  26. 26. A biological dressing obtained according to the method of claim 25.
  27. 27. A pharmacological composition comprising:
    a) a benzoin;
    b) 1% clotrimazole; and
    c) 60% ethanol.
  28. 28. A method of treating athlete's foot, said method comprising the steps of:
    contacting sites on the skin exhibiting symptoms of athlete's foot with a pharmacological composition according to claim 14 or 27; and
    allowing said composition to dry so that it forms a film on said skin, so that said symptoms of athlete's foot are treated.
  29. 29. A unit dosage form comprising:
    a) a benzoin;
    b) from about 0.5% to about 2% clotrimazole ; and
    c) 60% ethanol.
  30. 30. The unit dosage form according to claim 29, which comprises 0.1% clotrimazole.
  31. 31. A pharmaceutical kit comprising:
    one or more container holding a pharmacological composition according to claim 1; and
    instructions for use in treating symptoms of a disease of skin or a mucous membrane of a mammal.
  32. 32. The pharmaceutical kit according to claim 31, wherein said one or more container is a delivery system selected from the group consisting of a roll-on applicator, a spray applicator, an aerosol applicator, a sponge tip applicator and a syringe.
US10279704 2001-06-18 2002-10-23 Gum resin as a carrier for topical application of antimicrobial agents Active 2023-08-07 US8648082B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US29937701 true 2001-06-18 2001-06-18
US10053313 US6899897B2 (en) 2001-06-18 2002-01-18 Gum resin as a carrier for topical application of pharmacologically active agents
US10279704 US8648082B2 (en) 2001-06-18 2002-10-23 Gum resin as a carrier for topical application of antimicrobial agents

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10279704 US8648082B2 (en) 2001-06-18 2002-10-23 Gum resin as a carrier for topical application of antimicrobial agents
US13464514 US8846092B2 (en) 2001-06-18 2012-05-04 Gum resin as a carrier for topical application of pharmacologically active agents
US14478301 US20150051200A1 (en) 2001-06-18 2014-09-05 Gum resin as a carrier for topical application of pharmacologically active agents
US15343371 US20170296674A1 (en) 2001-06-18 2016-11-04 Gum resin as a carrier for topical application of pharmacologically active agents

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10053313 Continuation-In-Part US6899897B2 (en) 2001-06-18 2002-01-18 Gum resin as a carrier for topical application of pharmacologically active agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13464514 Continuation US8846092B2 (en) 2001-06-18 2012-05-04 Gum resin as a carrier for topical application of pharmacologically active agents

Publications (2)

Publication Number Publication Date
US20030068331A1 true true US20030068331A1 (en) 2003-04-10
US8648082B2 US8648082B2 (en) 2014-02-11

Family

ID=26731702

Family Applications (5)

Application Number Title Priority Date Filing Date
US10053313 Active US6899897B2 (en) 2001-06-18 2002-01-18 Gum resin as a carrier for topical application of pharmacologically active agents
US10279704 Active 2023-08-07 US8648082B2 (en) 2001-06-18 2002-10-23 Gum resin as a carrier for topical application of antimicrobial agents
US13464514 Active US8846092B2 (en) 2001-06-18 2012-05-04 Gum resin as a carrier for topical application of pharmacologically active agents
US14478301 Abandoned US20150051200A1 (en) 2001-06-18 2014-09-05 Gum resin as a carrier for topical application of pharmacologically active agents
US15343371 Pending US20170296674A1 (en) 2001-06-18 2016-11-04 Gum resin as a carrier for topical application of pharmacologically active agents

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10053313 Active US6899897B2 (en) 2001-06-18 2002-01-18 Gum resin as a carrier for topical application of pharmacologically active agents

Family Applications After (3)

Application Number Title Priority Date Filing Date
US13464514 Active US8846092B2 (en) 2001-06-18 2012-05-04 Gum resin as a carrier for topical application of pharmacologically active agents
US14478301 Abandoned US20150051200A1 (en) 2001-06-18 2014-09-05 Gum resin as a carrier for topical application of pharmacologically active agents
US15343371 Pending US20170296674A1 (en) 2001-06-18 2016-11-04 Gum resin as a carrier for topical application of pharmacologically active agents

Country Status (5)

Country Link
US (5) US6899897B2 (en)
EP (3) EP1408897A4 (en)
JP (2) JP2005500292A (en)
CA (1) CA2451040C (en)
WO (1) WO2002102304A3 (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050095208A1 (en) * 2003-11-03 2005-05-05 Alex Battaglia Oral care compositions for topical application
US20050159368A1 (en) * 2004-01-20 2005-07-21 Stanley Johnston Wound treatment composition and process of manufacture
US20050244521A1 (en) * 2003-11-07 2005-11-03 Strickland James A Tobacco compositions
US20060191548A1 (en) * 2003-11-07 2006-08-31 Strickland James A Tobacco compositions
US20080166395A1 (en) * 2007-01-04 2008-07-10 Roush Steven H Article for delivering substrates to the oral cavity
US20080286299A1 (en) * 2003-11-03 2008-11-20 Jaleva, Llc Film-forming resins as a carrier for topical application of pharmacologically active agents
US20090131909A1 (en) * 2007-11-05 2009-05-21 Sten Bjornberg Device for the treatment of vaginal fungal infection
US20100062044A1 (en) * 2008-09-11 2010-03-11 Smith Jan G Method and a product to reduce and treat problems associated with tinea pedis
US20110152925A1 (en) * 2009-12-22 2011-06-23 Schorr Phillip A Skin Preparation That Immobilizes Bacteria
CN102948927A (en) * 2011-08-26 2013-03-06 香港理工大学 Item of clothing for daily pharmacological treatment of a fungal infection
US20140221906A1 (en) * 2013-02-06 2014-08-07 Jake W. Townsend Patch system for the treatment of warts and method for same
US8846092B2 (en) 2001-06-18 2014-09-30 Jaleva Pharmaceuticals, Llc Gum resin as a carrier for topical application of pharmacologically active agents

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040043947A1 (en) * 2002-08-29 2004-03-04 Gersh Steven A. Methods of treating wounds or ulcers of the foot, ankle or lower extremity of the leg
US20060177527A1 (en) * 2005-02-04 2006-08-10 Shoshana Moses Methods and compositions for treating psoriasis
US20080199549A1 (en) * 2007-02-16 2008-08-21 Bionature E. A. Limited Treatment and prevention of inflammation
US7736632B2 (en) * 2008-02-20 2010-06-15 Gorman Cynthia Delaney Topical deodorant composition, and method of its manufacture and use
WO2011027247A1 (en) 2009-09-03 2011-03-10 Sulur Subramaniam Vanangamudi An antifungal cream comprising terbinafine hydrochloride
WO2011101826A1 (en) 2010-02-22 2011-08-25 Sulur Subramaniam Vanangamudi A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer, terbinafine and dexamethasone, and a process to make it
WO2012049542A1 (en) 2010-10-15 2012-04-19 Sulur Subramaniam Vanangamudi A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer, mometasone as a corticosteroid and clotrimazol as antifungal agent, and a process to make it
WO2012049544A1 (en) 2010-10-15 2012-04-19 Sulur Subramaniam Vanangamudi A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer, a hydrocortisone acetate as a corticosteroid, and clotrimazole as an antifungal agent, and a process to make it
DE102011106657A1 (en) * 2011-07-05 2013-01-10 Otto Berger Mixture, useful to treat e.g. nail fungus, comprises e.g. Larix, Abies, Picea, Pinus, Pinus sylvestris, Alnus, gum resin, Boswellia sp., folia melissae, herba urticae, herba verbenae, carlinae radix, Potentilla erecta and 2-propanol
EP2765989B1 (en) * 2011-10-13 2016-04-13 Jaleva Pharmaceuticals LLC Methods and compositions for rapid transbuccal delivery of active agents

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3699958A (en) * 1970-12-31 1972-10-24 Laszlo G Szucs Antimicrobial woven or knitted fabric
US4307075A (en) * 1979-09-13 1981-12-22 American Home Products Corporation Topical treatment of aphthous stomatitis
US5063065A (en) * 1990-10-09 1991-11-05 Bazterrica Enrique J V Composition and method for the treatment of genital dysplasia
US5167649A (en) * 1988-08-22 1992-12-01 Zook Gerald P Drug delivery system for the removal of dermal lesions
US5178870A (en) * 1988-04-26 1993-01-12 Explore Antimicrobial composition with long-term activity
US5422100A (en) * 1990-03-02 1995-06-06 The Partnership Of Isaac G. Eliaz And Samuel Gonen Method and product for treating skin afflictions
US5429590A (en) * 1992-12-01 1995-07-04 Nitto Denko Corporation Medical water-absorptive polymer and dressing for wound and medical bandage using the same
US5446070A (en) * 1991-02-27 1995-08-29 Nover Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5760052A (en) * 1997-02-06 1998-06-02 Peacock; Robert Composition for use as a fungistat and for the treatment of fungal infections
US6143794A (en) * 1998-04-17 2000-11-07 Bertek Pharmaceuticals, Inc. Topical formulations for the treatment of nail fungal diseases
US20020018757A1 (en) * 2000-06-30 2002-02-14 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Cosmetic skin care compositions and containing gum mastic
US6746667B2 (en) * 2001-07-05 2004-06-08 Closure Medical Corporation Adhesive treatment for tinea pedis

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB981144A (en) 1963-03-25 1965-01-20 Licencia Talalmanyokat A pharmaceutical formulation for the treatment of dermatophytoses
US3538230A (en) 1966-12-05 1970-11-03 Lever Brothers Ltd Oral compositions containing silica xerogels as cleaning and polishing agents
US3389049A (en) 1967-04-27 1968-06-18 Harold E. Frantz Treatment of topical fungus infections with dichlorodiphenyltrichloroethane
US3535412A (en) 1968-02-15 1970-10-20 Cities Service Co Process for producing improved pellets of a powder
US3678154A (en) 1968-07-01 1972-07-18 Procter & Gamble Oral compositions for calculus retardation
US3689637A (en) 1969-07-11 1972-09-05 Lever Brothers Ltd Dentifrice composition
US3911104A (en) 1970-09-21 1975-10-07 Colgate Palmolive Co Gel dentifrices
US3711604A (en) 1971-07-19 1973-01-16 Colgate Palmolive Co Fluoride containing transparent dentifrice
US3935306A (en) 1972-04-11 1976-01-27 Colgate-Palmolive Company Toothpaste formulations
US4040858A (en) 1974-10-31 1977-08-09 J. M. Huber Corporation Preparation of precipitated silicas having controlled refractive index
FR2222085B1 (en) 1973-03-21 1976-04-09 Levrier Andree
US4307717A (en) 1977-11-07 1981-12-29 Lectec Corporation Sterile improved bandage containing a medicament
US4514385A (en) 1981-10-05 1985-04-30 Alcon Laboratories, Inc. Anti-acne compositions
US4496322A (en) * 1983-05-11 1985-01-29 University Of Toronto Innovations Foundation Benzoin antimicrobial dental varnishes
JPH0463852B2 (en) * 1983-09-14 1992-10-13 Hisamitsu Pharmaceutical Co
JPH0425930B2 (en) * 1984-04-27 1992-05-06 Terumo Corp
WO1986002090A1 (en) 1984-09-26 1986-04-10 Gluck Bruno A Antiseptic cleansing compositions
JPH0418699B2 (en) 1985-01-16 1992-03-27 Nippon Denki Kk
CA1328813C (en) 1986-11-06 1994-04-26 Hiroshi Tanaka Skin irritation alleviation agent and composition thereof
NL8801087A (en) 1988-04-26 1989-11-16 Explore Antimicrobial composition with long-term efficacy.
US5438076A (en) 1988-05-03 1995-08-01 Perio Products, Ltd. Liquid polymer composition, and method of use
DE3827561C1 (en) * 1988-08-13 1989-12-28 Lts Lohmann Therapie-Systeme Gmbh & Co Kg, 5450 Neuwied, De
US5116603A (en) * 1989-01-31 1992-05-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem Oral antifungal preventative, and method of use
US5411738A (en) 1989-03-17 1995-05-02 Hind Health Care, Inc. Method for treating nerve injury pain associated with shingles (herpes-zoster and post-herpetic neuralgia) by topical application of lidocaine
CA1338779C (en) 1989-03-17 1996-12-10 Harry Hind Method for treating pain associated with herpes-zoster and post-herpetic neuralgia by topical application of local anesthetics
US5234957A (en) * 1991-02-27 1993-08-10 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
EP0525267A3 (en) 1991-08-02 1993-04-21 Ferndale Laboratories, Inc. Prolonged occlusion treatment system
FR2687571B1 (en) 1992-02-21 1994-04-22 Kandelman Daniel
JP3698720B2 (en) 1992-07-03 2005-09-21 ミニステロ・デル・ウニヴェルシタ・エ・デッラ・リチェルカ・シエンティフィカ・エ・テクノロジカ Hyaluronic acid and its derivatives in interpenetrating polymer network (ipn)
US5776430A (en) 1994-11-01 1998-07-07 Calgon Vestal, Inc. Topical antimicrobial cleanser containing chlorhexidine gluconate and alcohol
JP3573803B2 (en) 1994-02-16 2004-10-06 ポーラ化成工業株式会社 External preparation for skin
US5639310A (en) 1994-06-10 1997-06-17 Giampaolo, Jr.; Joseph L. Method for manually disinfecting and cleaning post or pierced earrings
JP3515821B2 (en) 1994-10-21 2004-04-05 株式会社資生堂 Disinfectant composition
JPH09255565A (en) * 1996-03-26 1997-09-30 Daikyo Yakuhin Kogyo Kk Hydrogel patch for dermal local anesthesia
US5942239A (en) 1996-05-09 1999-08-24 Iowa State University Research Foundation, Inc. Method and composition for coating wound or protecting animal skin
JPH10130173A (en) * 1996-10-28 1998-05-19 Japan Medic Kk Quick-drying disinfectant
US7163705B2 (en) * 1998-12-15 2007-01-16 Wm. Wrigley Jr. Company Coated chewing gum product and method of making
FR2757046B1 (en) 1996-12-16 1999-03-05 Dior Christian Parfums Use of an extract of resin okoume in the cosmetic and pharmaceutical fields, especially dermatological
EP0923937B1 (en) 1997-12-08 2004-03-10 Council of Scientific and Industrial Research A herbal formulation useful as a therapeutic and cosmetic application for the treatment of general skin disorders
US6379673B1 (en) 1997-12-08 2002-04-30 Council Of Scientific And Industrial Research Herbal formulation useful as a therapeutic and cosmetic applications for the treatment of general skin disorders
US6030633A (en) * 1998-05-18 2000-02-29 West Agro, Inc. Film-forming compositions for protecting animal skin
JP2002518417A (en) * 1998-06-25 2002-06-25 ラヴィファム ラボラトリーズ インコーポレーテッド Treatment equipment and methods of erectile dysfunction
US20020082279A1 (en) 1999-10-15 2002-06-27 Neal B. Schultz Method and composition for the treatment of dermatologic diseases
US6517350B2 (en) 2000-05-26 2003-02-11 Dentovations Inc. Method for whitening teeth
EP1370226A2 (en) 2001-01-24 2003-12-17 Oraceutical LLC Topical oral care compositions
US6899897B2 (en) 2001-06-18 2005-05-31 Jaleva, Inc. Gum resin as a carrier for topical application of pharmacologically active agents
US9554984B2 (en) 2003-11-03 2017-01-31 Jaleva Pharmaceuticals, Llc Oral care compositions for topical application
EP1947934A4 (en) 2005-11-07 2012-04-25 Jaleva Llc Film-forming resins as a carrier for topical application of pharmacologically active agents

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3699958A (en) * 1970-12-31 1972-10-24 Laszlo G Szucs Antimicrobial woven or knitted fabric
US4307075A (en) * 1979-09-13 1981-12-22 American Home Products Corporation Topical treatment of aphthous stomatitis
US5178870A (en) * 1988-04-26 1993-01-12 Explore Antimicrobial composition with long-term activity
US5167649A (en) * 1988-08-22 1992-12-01 Zook Gerald P Drug delivery system for the removal of dermal lesions
US5422100A (en) * 1990-03-02 1995-06-06 The Partnership Of Isaac G. Eliaz And Samuel Gonen Method and product for treating skin afflictions
US5063065A (en) * 1990-10-09 1991-11-05 Bazterrica Enrique J V Composition and method for the treatment of genital dysplasia
US5446070A (en) * 1991-02-27 1995-08-29 Nover Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5429590A (en) * 1992-12-01 1995-07-04 Nitto Denko Corporation Medical water-absorptive polymer and dressing for wound and medical bandage using the same
US5760052A (en) * 1997-02-06 1998-06-02 Peacock; Robert Composition for use as a fungistat and for the treatment of fungal infections
US6143794A (en) * 1998-04-17 2000-11-07 Bertek Pharmaceuticals, Inc. Topical formulations for the treatment of nail fungal diseases
US20020018757A1 (en) * 2000-06-30 2002-02-14 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Cosmetic skin care compositions and containing gum mastic
US6746667B2 (en) * 2001-07-05 2004-06-08 Closure Medical Corporation Adhesive treatment for tinea pedis

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8846092B2 (en) 2001-06-18 2014-09-30 Jaleva Pharmaceuticals, Llc Gum resin as a carrier for topical application of pharmacologically active agents
US20080286299A1 (en) * 2003-11-03 2008-11-20 Jaleva, Llc Film-forming resins as a carrier for topical application of pharmacologically active agents
US8709439B2 (en) 2003-11-03 2014-04-29 Jaleva Pharmaceuticals, Llc Film-forming resins as a carrier for topical application of pharmacologically active agents
US20050095208A1 (en) * 2003-11-03 2005-05-05 Alex Battaglia Oral care compositions for topical application
US9554984B2 (en) 2003-11-03 2017-01-31 Jaleva Pharmaceuticals, Llc Oral care compositions for topical application
US8627828B2 (en) 2003-11-07 2014-01-14 U.S. Smokeless Tobacco Company Llc Tobacco compositions
US20060191548A1 (en) * 2003-11-07 2006-08-31 Strickland James A Tobacco compositions
US8469036B2 (en) 2003-11-07 2013-06-25 U.S. Smokeless Tobacco Company Llc Tobacco compositions
US8636011B2 (en) 2003-11-07 2014-01-28 U.S. Smokeless Tobacco Company Llc Tobacco compositions
US20050244521A1 (en) * 2003-11-07 2005-11-03 Strickland James A Tobacco compositions
US20050159368A1 (en) * 2004-01-20 2005-07-21 Stanley Johnston Wound treatment composition and process of manufacture
WO2005069982A2 (en) * 2004-01-20 2005-08-04 Stanley Johnston Wound treatment composition and process of manufacture
WO2005069982A3 (en) * 2004-01-20 2008-01-24 Stanley Johnston Wound treatment composition and process of manufacture
US20080317690A1 (en) * 2005-11-07 2008-12-25 Alex Battaglia Film-Forming Resins as a Carrier for Topical Application of Pharmacologically Active Agents
US20080166395A1 (en) * 2007-01-04 2008-07-10 Roush Steven H Article for delivering substrates to the oral cavity
US8748689B2 (en) 2007-11-05 2014-06-10 Abigo Medical Ab Device for the treatment of vaginal fungal infection
US20090131909A1 (en) * 2007-11-05 2009-05-21 Sten Bjornberg Device for the treatment of vaginal fungal infection
US20100062044A1 (en) * 2008-09-11 2010-03-11 Smith Jan G Method and a product to reduce and treat problems associated with tinea pedis
US8263115B2 (en) 2008-09-11 2012-09-11 Abigo Medical Ab Method and a product to reduce and treat problems associated with tinea pedis
US20110152925A1 (en) * 2009-12-22 2011-06-23 Schorr Phillip A Skin Preparation That Immobilizes Bacteria
CN102948927A (en) * 2011-08-26 2013-03-06 香港理工大学 Item of clothing for daily pharmacological treatment of a fungal infection
US20140221906A1 (en) * 2013-02-06 2014-08-07 Jake W. Townsend Patch system for the treatment of warts and method for same

Also Published As

Publication number Publication date Type
EP2363118A1 (en) 2011-09-07 application
US20120220578A1 (en) 2012-08-30 application
US6899897B2 (en) 2005-05-31 grant
US8648082B2 (en) 2014-02-11 grant
EP2441448A1 (en) 2012-04-18 application
EP1408897A2 (en) 2004-04-21 application
WO2002102304A2 (en) 2002-12-27 application
CA2451040C (en) 2012-10-09 grant
US20150051200A1 (en) 2015-02-19 application
US20030099666A1 (en) 2003-05-29 application
WO2002102304A3 (en) 2003-05-08 application
US20170296674A1 (en) 2017-10-19 application
US8846092B2 (en) 2014-09-30 grant
CA2451040A1 (en) 2002-12-27 application
JP2010155853A (en) 2010-07-15 application
JP2005500292A (en) 2005-01-06 application
EP1408897A4 (en) 2006-12-06 application

Similar Documents

Publication Publication Date Title
US7005408B2 (en) Warming and nonirritating lubricant compositions and method of comparing irritation
US4831023A (en) Water washable vehicles for topical use
US6767552B2 (en) Adhesive treatment for oral fungal infection
US5081158A (en) Compositions and in situ methods for forming films on body tissue
US4247547A (en) Tretinoin in a gel vehicle for acne treatment
US5891920A (en) Medicinal adjuvants consisting of N-subsitituted-o-toluidine derivatives, and percutaneously absorbable preparations comprising the adjuvants
US7074392B1 (en) Controllled delivery system of antifungal and keratolytic agents for local treatment of fungal infections
US6846837B2 (en) Topical administration of basic antifungal compositions to treat fungal infections of the nails
US4873265A (en) Anti-infective methods and compositions
US4933184A (en) Menthol enhancement of transdermal drug delivery
US5460620A (en) Method of applying in-tandem applicator pads for transdermal delivery of a therapeutic agent
US20030072814A1 (en) Topical pharmaceutical composition for the treatment of warts
US6582711B1 (en) Hydroalcoholic compositions thickened using polymers
US5874074A (en) Occlusive/semi-occlusive lotion for treatment of a skin disease or disorder
US7198800B1 (en) Compositions and methods
US7094422B2 (en) Topical delivery of antifungal agents
US20070225379A1 (en) Transdermal delivery of systemically active central nervous system drugs
US20050025833A1 (en) Pharmaceutical composition and method for transdermal drug delivery
US5081157A (en) Compositions and in situ methods for forming films on body tissue
US20080132580A1 (en) Dispersion For Delivering Active Agents
US6942875B2 (en) Adhesive treatment for skin yeast infections
US5866105A (en) Pharmaceutical composition
US5536502A (en) Skin-tear medicament and method of use
US20070196452A1 (en) Flux-enabling compositions and methods for dermal delivery of drugs
US4895727A (en) Pharmaceutical vehicles for exhancing penetration and retention in the skin

Legal Events

Date Code Title Description
AS Assignment

Owner name: JALEVA, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BATTAGLIA, ALEX;BEIM, EVA;REEL/FRAME:015172/0239;SIGNING DATES FROM 20040315 TO 20040320

Owner name: JALEVA, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BATTAGLIA, ALEX;BEIM, EVA;SIGNING DATES FROM 20040315 TO 20040320;REEL/FRAME:015172/0239

AS Assignment

Owner name: JALEVA, LLC, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:JALEVA, INC.;REEL/FRAME:021018/0264

Effective date: 20080412

AS Assignment

Owner name: JALEVA PHARMACEUTICALS, LLC, CALIFORNIA

Free format text: CHANGE OF NAME;ASSIGNOR:JALEVA, LLC;REEL/FRAME:032568/0870

Effective date: 20100309

FPAY Fee payment

Year of fee payment: 4

AS Assignment

Owner name: ADVANCED RESIN THERAPEUTICS, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:JAVELA PHARMACEUTICALS, LLC;REEL/FRAME:046087/0363

Effective date: 20170423

AS Assignment

Owner name: ADVANCED RESIN THERAPEUTICS, INC., CALIFORNIA

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE CONVEYING PARTY PREVIOUSLY RECORDED AT REEL: 046087 FRAME: 0363. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT;ASSIGNOR:JALEVA PHARMACEUTICALS, LLC;REEL/FRAME:046407/0441

Effective date: 20170423